How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Pharmaceutical Aseptic Filling CMO Service Market
- By Dosage Form: Vials, Cartridges, Pre-filled Syringes, Ampoules, Bags
- By Therapeutic Area: Oncology, Vaccines, Cardiovascular, Central Nervous System (CNS), Anti-infectives
- By Filling Technology: Liquid Filling, Lyophilization (Freeze Drying), Blow-Fill-Seal (BFS), Powder Filling
- By Client Type: Biopharmaceutical Companies, Generic Pharmaceutical Companies, Contract Development and Manufacturing Organizations (CDMOs)
- By Sterilization Method: Terminal Sterilization, Aseptic Processing
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Vials leads By Dosage Form at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 13 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 287 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.176 →
- 12 Company Profiles 13 players: SWOT & benchmarking p.184 →
Full report · locked preview
Everything inside the Pharmaceutical Aseptic Filling CMO Service Market report
A complete, evidence-based study - 12 chapters and 120 sections covering market size, segmentation across 5 axes, regional analysis and 13 company profiles, forecast to 2033.
Segmentation covered
Dosage Form 5
Therapeutic Area 5
Filling Technology 4
Client Type 3
Sterilization Method 2
Companies profiled
Lonza Group
Catalent Pharma Solutions
Boehringer Ingelheim BioXcellence
Recipharm
Famar
Vetter Pharma International
Siegfried Holding AG
Baxter BioPharma Solutions
AMRI (now part of Evotec)
CordenPharma
PCI Pharma Services
Brenntag Pharma
+1 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
13 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Lonza Group
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Catalent Pharma Solutions
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Boehringer Ingelheim BioXcellence
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Recipharm
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Famar
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Vetter Pharma International
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Siegfried Holding AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Baxter BioPharma Solutions
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →AMRI (now part of Evotec)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →CordenPharma
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →PCI Pharma Services
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.214 →Brenntag Pharma
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →Aenova Group
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$5,884M by 2033 · 9.5% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Vials47.2
- Cartridges16.9
- Pre-filled Syringes13.1
- Ampoules15.4
- Bags7.3
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$942.6M → $1,984M · 9.8%
Europe$657.0M → $1,286M · 8.8%
Asia Pacific$599.8M → $1,258M · 9.7%
Latin America$371.3M → $757.9M · 9.3%
Middle East and Africa$285.6M → $614.8M · 10.1%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →9.422026
9.432027
9.432028
9.452029
9.462030
9.462031
9.492032
9.482033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Lonza Group10.0
- Catalent Pharma Solutions28.0
- Boehringer Ingelheim BioXcellence13.6
- Recipharm6.3
- Famar6.7
- Vetter Pharma International7.5
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Dosage Form19.7%
Therapeutic Area21.2%
Filling Technology31.0%
Client Type9.5%
Sterilization Method18.7%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.6
- Europe21.8
- Asia Pacific21.3
- Latin America12.8
- Middle East and Africa10.4
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Lonza Group | 80 | 78 | 93 | 92 | 97 | 93 | 89 |
| Catalent Pharma Solutions | 81 | 88 | 81 | 71 | 87 | 85 | 82 |
| Boehringer Ingelheim BioXcellence | 69 | 70 | 68 | 85 | 87 | 67 | 74 |
| Recipharm | 62 | 67 | 59 | 70 | 76 | 57 | 65 |
| Famar | 51 | 53 | 60 | 52 | 59 | 63 | 56 |
| Vetter Pharma International | 56 | 61 | 48 | 56 | 56 | 55 | 55 |
| Siegfried Holding AG | 43 | 50 | 58 | 63 | 46 | 45 | 51 |
| Baxter BioPharma Solutions | 39 | 38 | 43 | 55 | 54 | 52 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Lonza Group
- Catalent Pharma Solutions
- Boehringer Ingelheim BioXcellence
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Lonza Group | ✓ | ◐ | ✓ | ✓ | ✓ | ✓ |
| Catalent Pharma Solutions | ◐ | ✓ | ✓ | ◐ | ◐ | ✓ |
| Boehringer Ingelheim BioXcellence | ◐ | ◐ | ◐ | ✓ | ◐ | ◐ |
| Recipharm | ◐ | ◐ | − | − | ◐ | − |
| Famar | − | − | − | − | ◐ | ◐ |
| Vetter Pharma International | ◐ | ◐ | ◐ | ◐ | − | ◐ |
| Siegfried Holding AG | ◐ | ◐ | − | ◐ | ◐ | − |
| Baxter BioPharma Solutions | − | − | − | − | ◐ | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Lonza Group89
2Catalent Pharma Solutions82
3Boehringer Ingelheim BioXcellence74
4Recipharm65
5Famar56
6Vetter Pharma International55
7Siegfried Holding AG51
8Baxter BioPharma Solutions47
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Lonza GroupCatalent Pharma Solutions
Challenger1
Strong scale, closing on the leaders.
Boehringer Ingelheim BioXcellence
Contender1
Focused players with pockets of strength.
Recipharm
Niche4
Specialists in a single segment or region.
FamarVetter Pharma InternationalSiegfried Holding AGBaxter BioPharma Solutions
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Dosage Form in North America, then scale across Pharmaceutical Aseptic Filling CMO Service Market — a $233M beachhead inside a $4.08B market.
Beachhead (SOM)$233Mobtainable near-term
Serviceable (SAM)$1.39Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Vials
Best fit — highest urgency & budget in Dosage Form.
Economic buyer80 fit
Cartridges
Strong fit — clear ROI and a fast path to value.
End user65 fit
Pre-filled Syringes
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Dosage Form in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Therapeutic Area & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Filling Technology
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel27%
Digital / self-serve23%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Dosage Form leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Pharmaceutical Aseptic Filling CMO Service Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified38%
Sales qualified21%
Evaluation14%
Closed-won7%
$13.0KCAC
$61KLTV
4.7:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Pharmaceutical Aseptic Filling CMO Service Market is a resilient opportunity — $8.54B by 2033, compounding at 5.5%.
TAM · 2025$5.56Btoday
TAM · 2033$8.54Bforecast
CAGR5.5%2027–2033
Cumulative$62.6Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$8.54BTotal addressable market
SAM$3.13BServiceable available market
SOM$625MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →5.5% CAGR
Demand compounds through 2033, outpacing GDP across Dosage Form.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Dosage Form moving from early to mainstream — durable secular demand.
Consolidation upside
13+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$8.54BLarge & growingTAM by 2033 at 5.5% CAGR
$3.13BServiceable nowreachable with today’s model
$625MBeachhead winobtainable near-term share
13+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$6.66BBear3.6% CAGR
$8.54BBase5.5% CAGR
$10.9BBull7.3% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Therapeutic Area optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Pharmaceutical Aseptic Filling CMO Service Market — a $6.75B market by 2033. Plan: grow share from 9.1% to 18.0%.
Market size · 2033$6.75Btotal addressable
Market CAGR5.4%2027–2033
Target share18.0%from 9.1% today
Revenue ambition$1.21Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.1% | 18.0% | On track |
| Revenue | $592M | $1.21B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Ahead |
| Gross margin | 35.1% | 45.8% | At risk |
| Customer retention | 90.1% | 95.2% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Dosage Form
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Therapeutic Area capability
A defensible second engine — invest in Therapeutic Area to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Dosage Form share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Therapeutic Area
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $153M capacity & capability investment
- Greenlight bolt-on M&A in Therapeutic Area
- Authorise North America expansion plan
- Fund R&D program for Dosage Form leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Pharmaceutical Aseptic Filling CMO Service Market conversation — a $11.2B market you can size, segment and defend in minutes.
Market size · 2033$11.2Btotal opportunity
Growth11.0%CAGR to 2033
Addressable buyers1,107+accounts in scope
Typical ROI5.4×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Dosage Form
Goal Grow share in Dosage Form
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.4×return on cost, year one
< 3 mopayback period
$96K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
13+players profiled in this market
Coverage includes
Lonza GroupCatalent Pharma SolutionsBoehringer Ingelheim BioXcellenceRecipharmFamarVetter Pharma InternationalSiegfried Holding AGBaxter BioPharma Solutions+5 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Pharmaceutical Aseptic Filling CMO Service Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Pharmaceutical Aseptic Filling CMO Service Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Pharmaceutical Aseptic Filling and Closing Machine Market
Market size, share, segmentation and regional forecast.
$527M market · 2025 base year
View reportPharmaceutical Aseptic Fill and Finish CMO Service Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportPharmaceutical Anti-Counterfeiting Solution Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportPharmaceutical and Food Grade Propylene Glycol Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportPharmaceutical and Consumer Products Coding Equipment Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportPharmaceutical and Chemical Aluminum Bottles and Cans Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportPharmaceutical and Biopharmaceutical Safety Testing Service Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportPharmaceutical and Biomedical THz Spectrometer Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportPharmaceutical Analytical Testing Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportPharmaceutical Analytical Service Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportPharmaceutical Ampoules Market
Market size, share, segmentation and regional forecast.
$935M market · 2025 base year
View reportPharmaceutical Ampoules Filling and Sealing Machines Market
Market size, share, segmentation and regional forecast.
$344M market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.